William Blair & Company’s Exagen XGN Stock Holding History

William Blair & Company’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$254K	–	1777
2019 Q4	$254K	Buy	+10,000	New	+$178K	﹤0.01%	1230

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

William Blair & Company's XGN Position: Q1 2020 in Review

William Blair & Company sold out of Exagen (XGN) in Q1 2020, closing a stake of 10,000 shares — an estimated $254K sold.

William Blair & Company first reported a position in XGN in Q4 2019 and held it in 1 quarter. The position peaked at $254K in Q4 2019. 32 funds tracked by Wall St. Rank hold XGN as of Q1 2020.

William Blair & Company reported no remaining Exagen position as of Q1 2020 after selling out during the quarter.
William Blair & Company sold 10,000 Exagen shares in Q1 2020, an estimated $254K.
William Blair & Company first reported a position in Exagen in Q4 2019 and held it in 1 quarter.
William Blair & Company's Exagen position peaked at $254K in Q4 2019.
32 funds tracked by Wall St. Rank held Exagen as of Q1 2020.

Based on William Blair & Company's 13F filing for Q1 2020, filed 11 May 2020.